Cowen restated their buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report sent to investors on Monday. Cowen currently has a $200.00 price objective on the pharmaceutical company’s stock.

Several other research firms have also recently weighed in on VRTX. Maxim Group restated a buy rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Royal Bank of Canada assumed coverage on shares of Vertex Pharmaceuticals in a report on Thursday, September 14th. They set an outperform rating and a $175.00 target price on the stock. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a hold rating to a strong-buy rating and set a $174.00 target price on the stock in a report on Tuesday, September 26th. DA Davidson started coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They set a buy rating and a $200.00 target price on the stock. Finally, Vetr cut shares of Vertex Pharmaceuticals to a sell rating in a research note on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the stock. Vertex Pharmaceuticals has an average rating of Buy and a consensus price target of $173.15.

Vertex Pharmaceuticals (VRTX) traded down $1.93 during trading hours on Monday, reaching $141.68. 1,475,100 shares of the company’s stock were exchanged, compared to its average volume of 1,792,068. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. The firm has a market capitalization of $36,319.37, a PE ratio of 239.35, a price-to-earnings-growth ratio of 3.44 and a beta of 1.58. Vertex Pharmaceuticals has a 1-year low of $71.46 and a 1-year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business’s quarterly revenue was up 39.7% on a year-over-year basis. During the same period last year, the company posted $0.16 earnings per share. research analysts forecast that Vertex Pharmaceuticals will post 0.76 EPS for the current year.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 221 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total value of $32,551.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey M. Leiden sold 125,000 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the completion of the transaction, the chief executive officer now owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The disclosure for this sale can be found here. Insiders sold 343,519 shares of company stock valued at $49,488,660 over the last 90 days. 1.80% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after acquiring an additional 75 shares during the last quarter. Buckingham Asset Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 3.6% during the 2nd quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock worth $292,000 after purchasing an additional 79 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,383 shares of the pharmaceutical company’s stock worth $823,000 after purchasing an additional 101 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Vertex Pharmaceuticals by 4.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 2,661 shares of the pharmaceutical company’s stock worth $343,000 after purchasing an additional 113 shares during the period. Finally, Private Advisor Group LLC grew its holdings in shares of Vertex Pharmaceuticals by 2.4% during the 2nd quarter. Private Advisor Group LLC now owns 5,457 shares of the pharmaceutical company’s stock worth $702,000 after purchasing an additional 129 shares during the period. Hedge funds and other institutional investors own 93.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/12/vertex-pharmaceuticals-vrtx-buy-rating-reaffirmed-at-cowen.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.